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MaOBJECTIVES This study aimed to assess 6-month outcomes in patients with implantable cardioverter-deﬁbrillators
(ICDs) undergoing renal sympathetic denervation (RSD) for refractory ventricular arrhythmias (VAs).
BACKGROUND ICDs are generally indicated for patients at high risk of malignant VAs. Sympathetic hyperactivity
plays a critical role in the development, maintenance, and aggravation of VAs.
METHODS A total of 10 patients with refractory VA underwent RSD. Underlying conditions were Chagas disease (n ¼ 6),
nonischemic dilated cardiomyopathy (n ¼ 2), and ischemic cardiomyopathy (n ¼ 2). Information on the number of
ventricular tachycardia (VT)/ventricular ﬁbrillation (VF) episodes and device therapies (antitachycardia pacing/shocks) in
the previous 6 months as well as 1 and 6 months post-treatment was obtained from ICD interrogation.
RESULTS The median number of VT/VF episodes/antitachycardia pacing/shocks 6 months before RSD was 28.5 (range
1 to 106)/20.5 (range 0 to 52)/8 (range 0 to 88), respectively, and was reduced to 1 (range 0 to 17)/0 (range 0 to 7)/
0 (range 0 to 3) at 1 month and 0 (range 0 to 9)/0 (range 0 to 7)/0 (range 0 to 3) at 6 months afterward, respectively.
There were no major procedure-related complications. Two patients experienced sustained VT within the ﬁrst week; in
both cases, no further episodes occurred during follow-up. Two patients were nonresponders: 1 with persistent idio-
ventricular rhythm and 1 with multiple renal arteries and incomplete ablation. Three patients died during follow-up. None
of the deaths was attributed to VA.
CONCLUSIONS In patients with ICDs and refractory VAs, RSD was associated with reduced arrhythmic burden with
no procedure-related complications. Randomized controlled trials investigating RSD for treatment of refractory VAs in
patients with increased sympathetic activity are needed. (J Am Coll Cardiol Intv 2015;8:984–90) © 2015 by the
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AB BR E V I A T I O N S
AND ACRONYM S
ATP = antitachycardia pacing
ICD = implantable
cardioverter-deﬁbrillator
RSD = renal sympathetic
denervation
VA = ventricular arrhythmia
VF = ventricular ﬁbrillation
VT = ventricular tachycardia
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985I mplantable cardioverter-deﬁbrillators (ICDs)haveshown effectiveness for primary and secondaryprevention of sudden cardiac death and are
generally indicated for patients considered at high
risk of malignant arrhythmias (1). Treatment options
for patients presenting with recurrent ICD shocks
include pharmacologic treatment with antiarrhyth-
mic drugs and beta-blockers (2–4) as well as catheter-
based cardiac ablation (5,6). However, both ap-
proaches are associated with low long-term efﬁcacy
and, in the latter case, with potential complications
(7). New treatment options in this high-risk patient
population represent an unmet clinical need.
Sympathetic hyperactivity plays a critical role in
the development, maintenance, and aggravation of
ventricular arrhythmias (VAs) (8). Percutaneous renalSEE PAGE 991sympathetic denervation (RSD) has been shown to
decrease sympathetic activity (9) and thereby lower
ofﬁce and ambulatory blood pressure in certain pa-
tients with resistant hypertension for up to 3 years of
follow-up (10,11). The effects of RSD on sympathetic
nervous system activity suggest that this technique
could potentially be used in other disease states
associated with an increased sympathetic tone, such
as chronic kidney disease, heart failure, and ar-
rhythmias (12). Particularly for treatment of cardiac
arrhythmias, RSD has a strong pathophysiological
rationale (13). Recently, some case reports have sug-
gested short-term beneﬁts of RSD in patients with
electrical storm (14,15). However, the data are scarce,
and it is difﬁcult to derive any conclusive analysis.
The present study aimed to describe 6-month out-
comes in patients with ICDs undergoing RSD for
refractory VAs.
METHODS
The study was designed as a prospective, single-
center trial conducted in a tertiary hospital in São
Paulo, Brazil. Patients underwent RSD and were fol-
lowed for 6 months. The study was approved by the
local ethics committee and was conducted in accor-
dance with the ethical standards deﬁned by local
law. All patients provided written informed consent.
Ten consecutive patients with malignant VAs
refractory to optimal medical therapy who had previ-
ous failed cardiac ablation or who were considered
unsuitable for cardiac ablation due to polymorphic
ventricular tachycardia (VT), ventricular ﬁbrillation
(VF), unstable/unmappable arrhythmias, or cardiac
thrombus were eligible for the study. Those with
active infection, signiﬁcant hypotension (systolicblood pressure #80 mm Hg or demanding
vasopressors), a known allergy to contrast
agent, and main renal arteries unsuitable
for intervention (<20 mm length or <4 mm
diameter, stenosis >50%, ﬁbrodysplasia, and
previous stent) were excluded from the study.
Renal denervation was performed as pre-
viously described (16). After vascular line
placement, unfractionated heparin was
administered at a dose of 100 U/kg. Aortog-
raphy at the level of the renal arteries was
performed after administration of intravenous nitro-
glycerin (200 mg), followed by catheterization and
selective renal arteriography for the evaluation of the
anatomy. In 7 cases, the procedure was performed
using the irrigate-tip cardiac ablation catheter (Ther-
apy Cool Path, St. Jude Medical, Minneapolis, Min-
nesota). At least 4 radiofrequency lesions were
delivered along both renal arteries, starting from the
distal segments toward the ostia. The catheter was
pulled 5 mm and was rotated after each radio-
frequency delivery, thus producing a spiral conﬁgu-
ration of the ablations. In 3 patients, the procedure
was performed using the EnligHTN system (St. Jude
Medical), with minimum catheter manipulation. In
these cases, 8 lesions were applied to each renal ar-
tery. Due to the severe visceral pain generated by
ablation, analgesia with fentanyl and morphine was
performed in all cases. At the end of the procedure, a
control renal arteriography was performed to assess
the vascular integrity. The ICD monitoring zone was
programmed between 120 and 130 beats/min in all
patients.
STATISTICAL ANALYSIS. Continuous variables were
reported as mean  SD or median and range. Cate-
gorical variables were reported as frequencies and
percentages. Because of the limited sample size, all
analyses are descriptive in nature and no formal sta-
tistical tests are provided. All statistical analyses were
performed using IBM SPSS Statistics software version
22.0 (IBM, Armonk, New York).
RESULTS
BASELINE CHARACTERISTICS. Patient baseline charac-
teristics are summarized in Table 1. In total, 10 pa-
tients (5 male, age 64.5  6.3 years) with refractory
VAs requiring recurrent antitachycardia pacing (ATP)
or ICD shocks underwent RSD. One patient had
persistent idioventricular rhythm below the ICD
detection zone (and therefore received no ATP or
shocks), which was refractory to medical therapy
and cardiac ablation. Four patients had arterial hy-
pertension, and 1 patient had diabetes. ICDs were
TABLE 1 Baseline Characteristics
Patient #
Age
(yrs) Sex Etiology
Ejection Fraction
(%) Years of ICD
Previous
Cardiac Ablation
Cardiac
Thrombus Medications
1 70 Male CD 30 17 Yes No A, BB, ACEI, L
2 62 Male NIDCMP 34 3 No Yes A, BB, ACEI
3 61 Female CD 43 8 No No A, BB, P
4 62 Male IDCMP 22 1 No Yes A, BB, ACEI
5 56 Female CD 55 4 No No A, BB, ACEI
6 78 Male NIDCMP 23 6 No No A, BB
7 69 Female CD 29 5 No No A, ACEI
8 60 Female CD 30 5 No Yes A, BB
9 64 Male IDCMP 22 7 Yes No A, BB, ACEI
10 63 Female CD 22 0.08 (1 month) No No A, BB, ACEI, L
A ¼ amiodarone; ACEI ¼ angiotensin-converting enzyme inhibitor; BB ¼ beta-blocker; CD ¼ Chagas disease; IDCMP ¼ ischemic dilated cardiomyopathy; L ¼ lidocaine;
NIDCMP ¼ nonischemic dilated cardiomyopathy; P ¼ propafenone.
FIGURE 1 Individual Changes in SBP Pre- and Post-Procedure
mo ¼ months; SBP ¼ systolic blood pressure.
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986implanted an average of 5.6 years before RSD (range
1 month to 17 years). Patients were taking a mean of
2 antiarrhythmic drugs (range 1 to 3). The mean dose
of amiodarone was 510 mg daily. All patients but
1 were on long-term use of beta-blockers; 2 patients
were taking lidocaine and 1 was taking propafenone.
Mean ejection fraction was 31  10.8%. The etiology
of cardiomyopathy was Chagas disease in 6 patients,
nonischemic cardiomyopathy in 2, and ischemic
dilated cardiomyopathy in 2. Four patients had
physical signs of amiodarone-induced hyperpigmen-
tation. Two patients had undergone a previous un-
successful cardiac ablation. In 3 patients, cardiac
ablation was contraindicated due to the presence
of cardiac thrombus. The remaining 5 patients pre-
sented with either polymorphic VT or VF and were
deemed inappropriate candidates for cardiac catheter
ablation.
PROCEDURE CHARACTERISTICS. Mean right and left
renal artery diameters were 4.9  0.8 mm and 4.9 
0.6 mm, respectively. The mean lengths of the
right and left renal arteries were 41.3  8.5 mm and
31.4  11.9 mm, respectively. In 1 patient, 3 accessory
arteries were identiﬁed.
One patient had 2 accessory renal arteries, and
2 patients had 1 accessory renal artery. One patient
had mild (<50%) bilateral renal artery stenosis. The
average amount of dye used was 88.5 ml, and the
mean total ﬂuoroscopy time was 21.6  14.9 min. The
mean number of complete radiofrequency applica-
tions was 6.3  1.5 in the right renal artery and 5.2 
1.7 in the left renal artery.
PROCEDURE-RELATED COMPLICATIONS. One patient
developed severe bradycardia during the procedure,
requiring adrenaline infusion. Mild renal artery irreg-
ularities were frequently detected immediately afterthe radiofrequency application and were attributed to
vessel wall edema. None were considered blood-
ﬂow limiting at the end of the procedure. No
puncture site complications were documented.
Among all patients who completed the 6 months of
follow-up, no changes in systolic blood pressure
were observed during the entire follow-up (mean
systolic blood pressure 113.57  21.74 mm Hg at
baseline and 109.42  19.32 mm Hg at 6-month
follow-up). No patients required reduction in heart
failure medication due to signiﬁcant reduction in
blood pressure. Individual ofﬁce blood pressure is
represented in Figure 1. Kidney function measured
by creatinine concentration remained unchanged
during the study (mean creatinine 1.31  0.53 mg/dl
at baseline and 1.25  0.42 mg/dl at 6-month
follow-up).
FOLLOW-UP. Median follow-up was 180 days (range
18 days to 6 months). One patient died 18 days after
the procedure due to heart failure and sepsis sec-
ondary to pneumonia, and 1 patient died after 45 days
FIGURE 2 Burden of Ventricular Arrhythmias Before and
After Renal Denervation
mo ¼ months; VF ¼ ventricular ﬁbrillation; VT ¼ ventricular
tachycardia.
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987due to decompensated heart failure. A third patient
died 75 days after the procedure due to endocarditis.
None of the death events were attributed to VAs.
Among the survivors, all patients but 1 remained
on beta-blockers during the 6 months of follow-up.
Amiodarone was reduced in 5 patients and beta-
blockers in 2 patients. No patients required an
increase in antiarrhythmic medication. Table 2 illus-
trates individual changes in antiarrhythmic drugs
at 6 months of follow-up.
All patients that completed 6 months of follow-up
underwent renal artery ultrasound. No signiﬁcant
changes to the vessel lumen were observed.
BURDEN OF VAS AND ICD THERAPIES
ICD interrogation pre- and post-procedure was
available in 9 patients at 30 days and in 7 patients at
6 months of follow-up. The median number of VT/VF
episodes 6 months before the procedure was 28.5
(range 1 to 106) and reduced to 1 (range 0 to 17) and
0 (range 0 to 9) at 1 and 6 months, respectively
(Figure 2). The median number of ATPs 6 months
before the procedure was 20.5 (range 0 to 52) and
reduced to 0 (range 0 to 7) and 0 (range 0 to 7) at 1
and 6 months, respectively (Figure 3). The median
number of shocks 6 months prior to RSD was 8 (range
0 to 88) and reduced to 0 (range 0 to 3) and 0 (range
0 to 3) at 1 and 6 months, respectively (Figure 4).
Two patients experienced episodes of sustained VT
within the ﬁrst week after the procedure, and 1 of
these patients required a shock on 1 occasion. In
both cases, no more episodes occurred during the
entire follow-up. A total of 2 of the 10 patients
were considered to be nonresponders to RSD: 1 pa-
tient with ischemic cardiomyopathy and persistentTABLE 2 Antiarrhythmic Medications at Baseline and at
6 Months of Follow-Up
Patient # Medications
Dose at
Baseline (mg)
Dose at 6 Months
of Follow-Up (mg)
1 A, BB, L 600, 200, 300 400 ( ), 150 ( ), 0 ( )
2 A, BB 900, 100 200 ( ), 100
3 A, BB, P 200, 50, 900 0 ( ), 50, 900
4 A, BB 600, 200 300 ( ), 100 ( )
5 A 200 200
6 A, BB 600, 25 Death
7 A, BB 600, 25 200 ( ), 25
8 A, BB 600, 50 Death
9 A, BB 200, 100 200, 100
10 A, BB, L 600, 6.25, 300 Death
A ¼ amiodarone; BB ¼ beta-blocker; L ¼ lidocaine; P ¼ propafenone.idioventricular rhythm, and 1 patient with multiple
renal arteries in whom incomplete RSD was per-
formed (3 of the 5 renal arteries were treated).
One of the patients remained arrhythmia-free for
2 months after the procedure and developed VT
requiring external shock after this period in the
context of septic shock of urinary origin. No dif-
ferences in response were observed with regard to
type of catheter used.
DISCUSSION
This is the largest prospective, nonrandomized
study to demonstrate that, in patients with ICDs
and refractory ventricular arrhythmias, RSD is asso-
ciated with reduced arrhythmic burden and no
procedure-related complications. Importantly, ourFIGURE 3 Number of ATP Therapies Before and After
Renal Denervation
ATP ¼ antitachycardia pacing; mo ¼ months.
FIGURE 4 Number of Shocks Before and After
Renal Denervation
mo ¼ months.
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988study included patients with Chagas disease, non-
ischemic dilated cardiomyopathy, and ischemic
cardiomyopathy. Randomization to cardiac ablation
was not feasible once 50% of patients had either
previous failed cardiac ablation (2 of 10) or cardiac
thrombus (3 of 10). A sham procedure was not
considered due to patients’ condition (refractoriness
to optimal medical therapy).
The heart is highly innervated by sympathetic
nerve ﬁbers, and it is well established that sympa-
thetic activation increases heart rate and facilitates
atrioventricular conduction (17). In the ventricles,
increased sympathetic tone reduces ventricular ef-
fective refractory period, increases automaticity, and
reduces the threshold for VAs (18). Indeed, a growing
body of clinical and pre-clinical evidence indicates
that sympatho-modulation by either surgical cardiac
ablation or catheter-based RSD might represent new
treatment options (19). Vaseghi et al. (20) recently
demonstrated that surgical cardiac sympathetic
denervation reduces ICD shock burden by up to 90%.
Despite the promising results, the nonselective ef-
fects of surgical denervation may result in autonomic
dysfunction, as demonstrated in a small number of
patients in that study (changes in sweating pattern
in 10%, skin sensitivity in 12%, and persistent
ptosis in 1 patient). Ukena et al. (14) reported the ﬁrst-
in-man experience of percutaneous RSD in 2 patients
with heart failure and electrical storm: 1 patient
with hypertrophic cardiomyopathy, monomorphic
VT despite the use of multiple antiarrhythmics, and
unsuccessful endocardial and epicardial cardiac
ablation; and 1 patient with dilated cardiomyopathy,
frequent episodes of VF, and polymorphic VT who
declined to receive cardiac ablation therapy. In both
cases, a signiﬁcant reduction of VAs was documented.Our group reported substantial reduction of VT and
appropriate therapies from ICD in a patient with
dilated cardiomyopathy and with contraindication for
cardiac ablation (left ventricular thrombus) under-
going percutaneous RSD (15). Remo et al. (21) recently
showed the beneﬁts of RSD as adjunctive therapy for
refractory VT in 4 patients with underlying cardio-
myopathy, with similar results for ischemic and
nonischemic patients. In an experimental model, Linz
et al. (22) were able to show that RSD by use of radi-
ofrequency energy signiﬁcantly reduced the occur-
rence of spontaneous VAs and attenuated the rise in
left ventricular end-diastolic pressure during left
ischemic events. Interestingly, 6 of the 10 patients in
the current study suffered from Chagas disease.
Despite the implementation of socioeconomic mea-
sures and the development of drugs that allow
treatment of the acute phase of the disease, chronic
Chagas cardiomyopathy remains a major public
health problem in many Latin American countries,
affecting approximately 15 to 16 million people and
accounting for a mortality of 20,000 individuals/year
(23). About two-thirds of people with chronic symp-
toms develop cardiac damage, including dilation and
severe ventricular dysfunction, tachyarrhythmias,
bradyarrhythmias and, not uncommonly, sudden and
unexpected death (24). Sudden death accounts for
approximately 55% to 65% of overall death in patients
with Chagas disease, surpassing deaths from heart
failure (25). The arrhythmogenic nature of Chagas
disease is related to the presence of ﬁbrotic tissue
intermingled with preserved myocardial areas and
dyskinetic regions generating an area of high pro-
pensity of complex VAs (26). Treatment of VAs in-
cludes antiarrhythmic drugs, correction of reversible
causes such as electrolyte disturbances, and cardiac
ablation (27–29). Although amiodarone has been
shown to reduce the risk of sudden death and car-
diovascular death in this population by 29% and 18%,
respectively, the antiarrhythmic therapy is neutral
with respect to all-cause mortality and is associated
with a 2- and 5-fold increased risk of pulmonary and
thyroid toxicity, respectively (29). Approximately
50% of patients undergoing conventional endocardial
ablation have recurrence of their arrhythmia (30).
Not uncommonly, VTs in Chagasic patients have
multiple sites of origin, including the subepicardium,
and are hemodynamically unstable/unmappable (31).
The epicardial approach in these cases is often chal-
lenging, especially in those with severe ventricular
dysfunction and impaired clinical condition. RSD
might represent an alternative treatment option
for patients with Chagas disease presenting with
refractory VAs.
PERSPECTIVES
WHAT IS KNOWN? Sympathetic hyperactivity plays a
critical role in the development and maintenance of ventricular
arrhythmias. Some case reports have suggested short-term
beneﬁts of catheter-based renal sympathetic denervation (RSD)
in patients with electrical storm.
WHAT IS NEW? This is the largest prospective, non-
randomized study to demonstrate the feasibility and potential
efﬁcacy of renal sympathetic denervation to reduce ventricular
arrhythmia burden.
WHAT IS NEXT? If proven to be safe and effective in ran-
domized and well-controlled trials, renal sympathetic denerva-
tion might become an attractive strategy for the treatment of
refractory ventricular arrhythmias in patients with increased
sympathetic activity.
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989Two patients in our study showed no reduction
in the burden of arrhythmias during follow-up. One
patient had persistent idioventricular rhythm at
a mean heart rate of 90 beats/min. It is possible
that there was a lack of sympathetic trigger for
the initiation and maintenance of the VAs in this
particular case. The other patient remained asymp-
tomatic for 2 months after the procedure but
experienced a new episode of VAs thereafter. In the
latter case, signiﬁcant renal artery anatomy varia-
tion was observed (3 small renal arteries on the
right side and a small trunk on the left side with
early bifurcation), and incomplete ablation of renal
sympathetic nerves might at least partially account
for the observed response. Three patients died
of nonarrhythmic causes during follow-up, which
reﬂects the high-risk population with advanced
heart disease included in the study. Although
concomitant pharmacological therapy could inter-
fere with the results, no patients required an in-
crease in the number or dose of antiarrhythmic
medications.
The negative results observed in the Symplicity
HTN-3 study (A Controlled Trial of Renal Denerva-
tion for Resistant Hypertension) raises the question
of how this procedure could be more effective in
selected patients. The causes of nonresponse are not
yet fully understood; however, assumptions can be
made on the basis of knowledge of the pathophysi-
ology of hypertension and RSD procedure. Among
them, we emphasize: 1) the actual relevance of
sympathetic hyperactivity in the physiopathology of
resistant hypertension; 2) the inappropriate selection
of patients, including those with pseudoresistance
and secondary hypertension; and 3) conditions
related to the patient, such as nonadherence to
drug treatment and lifestyle changes. The standard
deviation in systolic blood pressure measured in the
RSD and control groups in both Symplicity HTN-1
and -2 were large and similar, indicating large var-
iations in the response. Another possible explana-
tion for the unexpected results of the Symplicity
HTN-3 trial includes the large number of partici-
pating centers and, therefore, the small number of
cases/center and the high percentage of nonexpert
operators with the technique. Finally, it is well
established that the reduction in blood pressure
is directly proportional to the number of radio-
frequency applications in the renal arteries. Unlike
the Symplicity HTN-3 study, in which the mean
number of radiofrequency applications was 3.9, in
this study an average of 6.3 and 5.2 lesions were
delivered to the right and left renal arteries,
respectively.STUDY LIMITATIONS. The nonrandomized design,
relatively small sample size, and absence of a control
arm represent potential limitations of the present
study. Although sympathetic activity was not directly
measured, a signiﬁcant association between RSD and
a reduction in the burden of VAs was notable. More
than one-half of the patients had Chagasic cardio-
myopathy, and the response to RSD could be different
in this population. It is possible that, besides the ef-
fects on autonomic tone, RSD could result in beneﬁ-
cial effects secondary to the reduction in volume
excess and hormonal activation seen in heart failure.
However, all patients but 1 had no signs of conges-
tion, suggesting that the reduction of arrhythmias
may not be primarily related to improvements in
heart failure.
CONCLUSIONS
Our ﬁndings illustrate the relevance of sympathetic
activation in patients with VAs and suggest a poten-
tial role for catheter-based RSD in reducing
arrhythmic burden. Larger studies on the effect of
RSD on VAs are needed and ongoing. If proven to be
safe and effective in randomized and well-controlled
trials, RSD might become an attractive strategy for
the treatment of refractory VAs in patients with
increased sympathetic activity.
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